US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
From 2seventy bio
Via Business Wire
News headline image
2seventy bio's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Where 2seventy bio Stands With Analysts ↗
 
Via Benzinga
News headline image
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
From 2seventy bio
Via Business Wire
News headline image
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
From 2seventy bio, Inc.
Via Business Wire
News headline image
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit ↗
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
News headline image
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
News headline image
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Expert Ratings for 2seventy bio ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
News headline image
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
2seventy bio Announces Proposed Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
News headline image
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients ↗
 
Via Benzinga
News headline image
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Provides Company Outlook for 2023
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
From 2seventy bio, Inc.
Via Business Wire
News headline image
4 Analysts Have This to Say About 2seventy bio ↗
Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >